Seeking Alpha

Skye Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab

Phase 2 study in patients with obesity and chronic kidney disease planned to initiate in first half of 2024 SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (SKYE) ("Skye"), a ...
Business Insider

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other ...
Seeking Alpha

Skye Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program

SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye" or the "Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and ...
Nasdaq

Skye Bioscience Partners with Arecor Therapeutics to Enhance Nimacimab Formulation for Obesity Treatment

Skye Bioscience, Inc. has announced a collaboration with Arecor Therapeutics plc to develop a higher concentration formulation of its CB1 inhibitor, nimacimab, utilizing Arecor's Arestat™ formulation ...
Nasdaq

Skye Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab

SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing drugs targeting the endocannabinoid system, announced today that it plans ...